BioBots Offers a New Bioprinting Option

New startup BioBots would like to make bioprinting more affordable.

BioBots’ prototype is already capable of building biomaterials. Courtesy of BioBots.


If you are attempting to pinpoint a single area in which additive manufacturing (AM) has made a large impact, it’s easy to argue for the medical field. 3D printing is offering new alternatives to doctors and medical designers, opening possibilities for new kinds of treatments and bespoke medical implants. The drawback, as is usual with new technology, is many of these new possibilities are expensive.

New startup BioBots would like to make bioprinting more affordable by offering a system that is capable of producing medical quality biomaterials without breaking the bank. The company’s prototype was on display at this year’s SXSW, and has garnered attention for printing a copy of Van Gogh’s ear.

BioBots' prototype is already capable of building biomaterials. Courtesy of  BioBots. BioBots’ prototype is already capable of building biomaterials. Courtesy of BioBots.

Rather than standard materials, such as plastic or metal, used by most AM systems, BioBots uses a special ink that is a mix of cells and sustaining fluids. The ink is jetted out in patterns which are then cured by blue light technology to harden into useful biomaterials, such as cartilage and tissue.

It isn’t yet possible to build viable replacement “parts” for humans, but biofabrication is valuable in producing bone scaffolding to assist recovery, or, more likely, to assist medical testing by generating cruelty-free materials that can be used in laboratories. Using actual human cells rather than animal cells for testing is a leap forward for the testing process.

“We really see it as a product for pharmaceutical companies right now, for companies that are doing clinical drug testing,” co-founder Danny Cabrera told TechCrunch. “You can use these devices to build 3D living tissue models using human cells, and you can use those models which are way more complex than 2D tissues or animals. They really recapitulate the function of the body. And you can use them to develop compounds for clinical settings. And catch the false positives before they get to clinical trials.”

BioBots is hardly the only player in the biofabrication game, but it is going the MakerBot route of offering affordability and ease-of-use. The company hopes to produce systems at a $5,000 price tag, with cartridges of the bioink for around $700. In a business where systems often cost tens of thousands of dollars, that’s a pretty good deal.

Below you’ll find a video about BioBots.

 

Share This Article

Subscribe to our FREE magazine, FREE email newsletters or both!

Join over 90,000 engineering professionals who get fresh engineering news as soon as it is published.


About the Author

John Newman

John Newman is a Digital Engineering contributor who focuses on 3D printing. Contact him via [email protected] and read his posts on Rapid Ready Technology.

Follow DE
#21124